GSA Capital Partners LLP Acquires Shares of 5,642 Moderna, Inc. (NASDAQ:MRNA)

GSA Capital Partners LLP bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 5,642 shares of the company’s stock, valued at approximately $377,000.

Other large investors also recently made changes to their positions in the company. Commerzbank Aktiengesellschaft FI grew its stake in shares of Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after purchasing an additional 93 shares during the period. CVA Family Office LLC grew its position in shares of Moderna by 21.6% during the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after buying an additional 96 shares during the period. Claro Advisors LLC grew its position in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after buying an additional 108 shares during the period. McAdam LLC raised its position in shares of Moderna by 1.1% in the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock valued at $1,315,000 after acquiring an additional 117 shares during the period. Finally, 180 Wealth Advisors LLC boosted its stake in Moderna by 1.1% during the 2nd quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after acquiring an additional 160 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Up 4.0 %

Moderna stock opened at $38.40 on Friday. The company has a fifty day simple moving average of $56.13 and a 200 day simple moving average of $95.05. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 1-year low of $35.80 and a 1-year high of $170.47. The company has a market cap of $14.78 billion, a P/E ratio of -6.60 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the previous year, the business earned ($1.39) earnings per share. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. Research analysts anticipate that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on MRNA shares. TD Cowen lowered their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. Sanford C. Bernstein began coverage on shares of Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective for the company. Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday. Finally, Piper Sandler reiterated an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $84.00.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 2,930 shares of company stock valued at $217,170 in the last 90 days. 15.70% of the stock is currently owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.